Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 23andMe Holding Co. ME

Consumer Cyclical Healthcare Advertising Agencies
23andMe Holding Co. is a genetics-led consumer healthcare and therapeutics company. The Company operates through two segments: Consumer & Research Services and Therapeutics. The Consumer & Research Services business segment comprises its Personal Genome Service (PGS), telehealth business, and research service. PGS services provide customers with a broad suite of genetic reports, including... see more

Recent & Breaking News (NDAQ:ME)

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient's complete health picture

GlobeNewswire May 16, 2023

23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results

GlobeNewswire May 11, 2023

23andMe Releases New Report Revealing Likelihood of Developing Lupus

GlobeNewswire May 9, 2023

Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

GlobeNewswire May 8, 2023

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

GlobeNewswire April 14, 2023

Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program

GlobeNewswire April 11, 2023

23andMe Publishes Inaugural Environmental, Social and Governance Report

PR Newswire March 29, 2023

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

GlobeNewswire March 24, 2023

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

GlobeNewswire March 14, 2023

New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare

GlobeNewswire March 9, 2023

23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies

GlobeNewswire February 28, 2023

23andMe to Present at Upcoming Investor Conferences

GlobeNewswire February 22, 2023

23andMe Reports FY2023 Third Quarter Financial Results

GlobeNewswire February 8, 2023

23andMe to Report FY2023 Third Quarter Financial Results

GlobeNewswire January 26, 2023

23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season

GlobeNewswire December 1, 2022

23andMe Reports FY2023 Second Quarter Financial Results

GlobeNewswire November 7, 2022

23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer's (SITC) 2022 Annual Meeting

GlobeNewswire November 7, 2022

23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication

GlobeNewswire October 27, 2022

23andMe to Report FY2023 Second Quarter Financial Results

GlobeNewswire October 24, 2022

23andMe to Present at Upcoming Investor Conferences

GlobeNewswire October 12, 2022